Angiotensin-converting enzyme inhibitor (ACE-I) therapy reduces complications of acute myocardial infarction (MI) even when the therapy is started very early after an acute event. This study sought to determine whether administration of ACE-I therapy prior to acute MI is related to subsequent patient morbidity and mortality.
METHODS:
Chart review of 318 consecutive patients admitted between September 1995 and December 1996 with a diagnosis of acute MI. Outcome data were compared between patient groups receiving ACE-I therapy prior to infarction and those who were not.
RESULTS:
Sixty-four patients (20%) were receiving prior ACE-I therapy. They experienced smaller MIs, as determined by peak creatine kinase elevation (1066 ± 134 vs. 1510 ± 95 IU; p < 0.05), and fewer Q-wave infarctions (p < 0.05) than did patients who were not receiving prior treatment. The severity of coronary artery disease, defined by an angiographic score, was similar for the two groups. Mortality rates, including patients resuscitated from ventricular fibrillation, were similar within the first 72 hours of admission (3% vs. 2%; p = NS), but patients receiving prior ACE-I therapy showed a greater long-term in-hospital mortality rate (14% vs. 5%; p < 0.05) related to more heart failure deaths. Multivariate logistic regression analysis identified age, treatment with digoxin prior to acute MI, and left ventricular ejection fraction after infarction, but not ACE-I therapy taken prior to infarction, as significant independent predictors of mortality and combined morbidity and mortality.
CONCLUSIONS:
In a group of patients experiencing an acute MI, those receiving prior ACE-I therapy were more likely to sustain fewer transmural MIs and smaller infarcts. Chronic ACE-I therapy may have cardioprotective effects during acute myocardial ischemia.
PfefferMABraunwaldEMoyeLABastaLBrownEJJrCuddyTEEffect of captopril on mortality and morbidity in patients with left ventricular dysfunction after myocardial infarction: Results of the Survival and Ventricular Enlargement trial. N Engl J Med1992;327:669–77.
2.
The Acute Infarction Ramipril Efficacy (AIRE) Investigators. Effects of ramipril on mortality and morbidity of survivors of acute myocardial infarction with clinical evidence of heart failure. Lancet1993;342:821–8.
3.
KoberLTorp-PedersenCCarlsenJEBaggerHEliasenPLyngborgKA clinical trial of the angiotensin-converting enzyme inhibitor trandolapril in patients with left ventricular dysfunction after myocardial infarction. Trandolapril Cardiac Evaluation (TRACE) study group. N Engl J Med1995;333:1670–6.
4.
GISSI-3. Effects of lisinopril and transdermal glyceril trinitrate singly and together on 6 week mortality and ventricular function after myocardial infarction. Lancet1994;343:1115–22.
5.
ISIS-4. Randomised factorial trial assessing oral captopril, oral mononitrate, and intravenous magnesium sulphate in 58,050 patients with suspected acute myocardial infarction. Lancet1995;345:669–85.
6.
AmbrosioniEBorghiCMagnaniB. The effect of the angiotensin-converting-enzyme inhibitor zofenopril on mortality and morbidity after anterior myocardial infarction. N Engl J Med1995;332:80–5.
7.
PfefferMALamasGAVaughanDEParisiAFBraunwaldE. Effect of captopril on progressive ventricular dilation after anterior myocardial infarction. N Engl J Med1988;319:80–6.
8.
PfefferJMPfefferMABraunwaldE. Influence of chronic captopril therapy in the infarcted left ventricle in the rat. Circ Res1985;57:84–95.
9.
GayRG. Early and late effects of captopril treatment after large myocardial infarction in rats. J Am Coll Cardiol1990;16:967–77.
10.
YusufSPepineCGarcesCPouleurHSalemDKostisJEffect of enalapril on myocardial infarction and unstable angina in patients with low ejection fractions. Lancet1992;340:1173–8.
11.
RutherfordJDPfefferMAMoyeLADavisBRFlakerGCKoweyPREffects of captopril on ischemic events after myocardial infarction: Results of the Survival and Ventricular Enlargement trial. Circulation1994;90:1731–8.
12.
PrzyklenkKKlonerRA. Angiotensin converting enzyme inhibitors improve contractile function of stunned myocardium by different mechanisms of action. Am Heart J1991;121:1319–30.
13.
de GraeffPAvan GilstWHde LangenCDJKingmaJHWesselingH. Concentration-dependent protection by captopril against myocardial damage during ischemia and reperfusion in a closed chest pig model. J Cardiovasc Pharmacol1987;9(suppl 2):S37–42.
14.
WesselingHde GraeffPAvan GilstWHKingmaJHde LangenCDJ. Cardiac arrhythmias — A new indication for angiotensin-converting enzyme inhibitors?J Hum Hypertens1989;3:89–95.
15.
McKennaWJHaywoodGA. The role of ACE inhibitors in the treatment of arrhythmias. Clin Cardiol1990;13:49–52.
16.
KochsMEggelingTHombachV. Pharmacological therapy in coronary heart disease: Prevention of life-threatening ventricular tachy-arrhythmias and sudden cardiac death. Eur Heart J1993;14:S107–19.
17.
BussmannWDMickeGHildenbrandRKlepzigH. Captopril in acute myocardial infarction: Beneficial effects on infarct size and arrhythmias. Clin Cardiol1995;18:465–70.
18.
JaffeAS. Biochemical detection of acute myocardial infarction. In: GershBJRahimtoolaSH, eds. Acute myocardial infarction. New York: Elsevier, 1991:110–27.
19.
LandmarkKAbdelnoorMKilhovdBDorumHP. Infarct size as estimated from peak creatine kinase and lactate dehydrogenase is probably reduced in patients using calcium antagonists at the onset of symptoms. Cardiovasc Drugs Ther1997;11:557–65.
20.
DissmannRLindenerTSchroderR. Estimation of enzymatic infarct size: Direct comparison of the marker enzymes creatine kinase and alpha-hydroxybutyrate dehydrogenase. Am Heart J1998;135:1–9.
21.
BlandJAltmanD. Statistical methods for assessing agreement between two methods of clinical measurements. Lancet1986;1:307–10.
22.
BallSG. Early or late ACE inhibition after myocardial infarction. J Cardiovasc Pharmacol1993;22(suppl 9):S18–21.
23.
ClelandJGF. ACE inhibitors for myocardial infarction: How should they be used?Eur Heart J1995;16:153–9.
24.
RemmeWJLookMPBootsmaMKruyssenHACMVerrostteLMEKraussXHNeurohumoral activation during acute myocardial ischaemia. Effects of ACE inhibition. Eur Heart J1990;11(suppl B):162–71.
25.
ManciniGBHenryGCMacayaCO'NeillBJPucilloALCarereRGAngiotensin-converting enzyme inhibition with quinapril improves endothelial vasomotor dysfunction in patients with coronary artery disease. The TREND study. Circulation1996;94:258–65.
26.
LinzWScholkensBA. Influence of local converting enzyme inhibition on angiotensin and bradykinin effects in ischemic rats. J Cardiovasc Pharmacol1987;10(suppl 7):S75–82.
27.
ScholkensBALinzWKonigW. Effects of the angiotensin converting enzyme inhibitor, ramipril, in isolated ischemic rat heart are abolished by a bradykinin antagonist. J Hypertens1988;6(suppl 4):S25–8.
28.
SchwartzSLWilliamsGH. Angiotensin-converting enzyme inhibition and prostaglandins. Am J Cardiol1982;49:1405–9.
29.
SchwartzSLWilliamsGHHollenbergNKLevineTBDluhyRCMooreTJ. Captopril-induced changes in prostaglandin production. J Clin Invest1980;65:1257–64.
30.
UngerTGohlkeP. Tissue renin—angiotensin systems in the heart and vasculature: Possible involvement in the cardiovascular actions of converting enzyme inhibitors. Am J Cardiol1990;65:3I–10I.
31.
DaviesMK. Effects of ACE inhibitors on coronary haemodynamics and angina pectoris. Br Heart J1994(suppl):S52–6.
32.
WestlinWMullaneK. Does captopril attenuate reperfusion-induced myocardial dysfunction by scavenging free radicals?Circulation1988;77(suppl I):I30–9.
33.
de GraeffPAvan GilstWHde LangenCDJKingmaJHWesselingH. Concentration dependent protection by captopril against ischemia-reperfusion injury in the isolated rat heart. Arch Int Pharmacodyn Ther1986;280:181–93.
34.
LucchesiBR. Myocardial ischemia, reperfusion and free radical injury. Am J Cardiol1990;65:14I–23I.
35.
ErtlGKlonerGAAlexanderRWBraunwaldE. Limitation of experimental infarct size by an angiotensin-converting enzyme inhibitor. Circulation1982;65:40–8.
36.
PerondiRSainoATioRAPamidossiGGregoriniLAlessioAACE inhibition attenuates sympathetic coronary vasoconstriction in patients with coronary artery disease. Circulation1992;85:2004–13.
37.
LevineTB. Neuroendocrine activation in acute myocardial infarction. Am J Cardiol1990;65:32I–4I.
38.
WhiteHDBarbashGICaliffRMSimesRJGrangerCBWeaverWDAge and outcome with contemporary thrombolytic therapy. Results from the GUSTO-1 trial. Circulation1996;94:1826–33.
39.
ElfellahMSOgilvieRI. Effect of vasodilator drugs on coronary occlusion and reperfusion arrhythmias in anaesthetised dogs. J Cardiovasc Pharmacol1985;7:826–32.
40.
RihalCSGershBJ. Role of acute myocardial ischemia in the pathogenesis of sudden cardiac death. In: MassodAMeyerburgRJRuskinJN, eds. Sudden cardiac death. Malvern, PA: Wilkins & Wilkins, 1994:293–317.
41.
Di MarcoJPHainesDE. Sudden cardiac death. Curr Problems Cardiol1990;15:185–232.
42.
KarlsbergRPGryerPERobertsR. Serial plasma catecholamine response early in the course of myocardial infarction: Relationship to infarct extent and mortality. Am Heart J1965;16:230–7.
43.
TobeTJMde LangenCDJWeersinkEGLvan WijngaardenJBelKJde GraeffPAThe angiotensin converting enzyme inhibitor perindopril improves survival after experimental myocardial infarction in pigs. J Cardiovasc Pharmacol1992;19:732–40.
44.
van WijngaardenJTobeTJMWeersinkEGLBelKJde GraeffPAde LangenCDJEffects of early angiotensin-converting enzyme inhibitor in a pig model of myocardial ischemia and reperfusion. J Cardiovasc Pharmacol1992;19:408–16.
45.
FlapanADNolanJNeilsonJMMEwingDJ. Effect of captopril on cardiac parasympathetic activity in chronic cardiac failure secondary to coronary artery disease. Am J Cardiol1992;69:532–5.
46.
BinkleyPFHaasGJStarlingRCNunziataEHattonPALeierCVSustained augmentation of parasympathetic tone with angiotensin-converting enzyme inhibition in patients with congestive heart failure. J Am Coll Cardiol1993;21:655–61.
47.
KaufmanESBosnerMSBiggerJTJrSteinPKKleigerRERolnitzkyLMEffects of digoxin and enalapril on heart period variability and response to head-up tilt in normal subjects. Am J Cardiol1993;72:95–9.
48.
PepineCJ. Ongoing clinical trials of angiotensin-converting enzyme inhibitors for treatment of coronary artery disease in patients with preserved left ventricular function. J Am Coll Cardiol1996;27:1048–52.
